Tampilkan postingan dengan label New England Journal of Medicine. Tampilkan semua postingan
Tampilkan postingan dengan label New England Journal of Medicine. Tampilkan semua postingan

Jumat, 18 Agustus 2017

Reference Pricing lowers pharmacy costs


Today's Managing Health Care Cost Number is $4.38




Source  First chart shows increased use of the reference price medication (lowest cost in class).  Second chart shows that average price for RETA Trust was higher at baseline, and decreased to less than Union Trust after implementation of reference pricing.  Patinets paid somewhat more in cost sharing.

Yesterday's New England Journal of Medicine reports on the effectiveness of using reference based pricing to steer patients toward the most cost-effective drug in a class. 

Researchers looked at prescriptions for 17,000 members of the RETA Trust (Catholic school and social service workers) who were subject to reference pricing for outpatient prescription drugs from 2013-2014, and compared changes in prescription patterns to 35,000 members of the Labor Trust, which used conventional tiers to steer pharmacy use to less costly medications.  Reference pricing should be more effective- it places the patient at risk for the entire difference in price between the prescribed drug and the lowest priced drug in a class- while tiers only place patients at risk for a portion of the difference in price.

The results are clear.   Reference pricing drove substantially more use of the most cost effective drugs; RETA Trust members started off using the most preferred drug in a class 2.6% less often, and at 18 months they were using the lowest priced reference drug  11.3% more often.   Researchers calculated savings of $1.34 million-  that calculates to savings of $4.38 per employee per month.

Reference pricing isn't easy to implement.  The communications challenges are large - as most patients and most doctors have little idea the incremental price between Crestor (brand name statin, almost $300 a month) and Atorvastin (generic version of Lipitor, about $20 a month. Prices from Costco.com.)  The RETA trust set up an override system to provide full coverage for any more expensive drug based on any physician note, regardless of its validity or relevance.  This makes it less likely that patients who genuinely would benefit from the higher priced drugs were denied access.

Total savings here aren't huge - assuming costs per employee of about $10,000 annually, this would represent about a half percent of total medical costs.  But Robinson, et al have demonstrated that this is an example where cost share changes behavior and lowers cost.






Senin, 07 Agustus 2017

Bringing down pharmaceutical costs

Bringing down pharmaceutical costs


Today's Managing Health Care Costs Number is  250%

One area of bipartisan agreement is the desire to lower pharmaceutical prices.   As always, there are good ideas with downsides, bad ideas with upsides, and many ideas that are likely to  have unanticipated consequences.   Annual prescription drug costs are expected to increase to $597 billion by 2025- a 250% increase from 2007, so there is a real imperative to address pharmaceutical costs. 

Among the ideas that are being discussed:

  1. Ease regulatory burden to allow faster generics to market. 
    The real problem here has generally been litigation from incumbent brand name products and lack of competition for non-blockbuster generics, most of which have only 1 or 2 manufacturers - leaving them vulnerable to steep price increases.  Let's make it harder to take legal steps to block new generics, easier to get approval for biosimilars, and allow importation of generics from other countries with good regulatory schemes when there is a shortage.
     
  2. Allow 'value based pricing.'
    No one is preventing value based pricing now- but we should think hard about whether this is really what we want.   Airlines use value based pricing (so that business travelers not staying over a Saturday night pay higher prices).   Some pharmaceutical companies want to be able to charge different prices based on the indication for a drug - but this is likely to lead to higher overall costs (and huge administrative headaches).  Her's a pretty positive assessment of  indication specific pricing from ICER (2015), and here's a perspective from New England Journal of Medicine (2017) pointing to likely higher overall costs. Reports from countries that implemented warrantees are disappointing; these were hard to reconcile and probably led to higher prices. A report from Propublica  begins:

More than a decade ago, Italy tried a novel approach to help bring down drug costs: asking pharmaceutical companies to return money to the national health system if some of their medicines failed to work as expected. The effort largely flopped

  1. "March in" and demand that patent-holders offer drugs for less, or seize the patent
    Some countries like Brazil and India have effectively done this- but they are much smaller markets than the US and they tend to be home to generic and not brand manufacturers.   This might be a more effective threat than actual policy.  Some Democrats have suggested that the NIH should exercise its 'march in' rights. Many think this would lead to decreased investment in pharma and less innovation - and such a move seems unlikely in an Administration seeking to diminish the role of government.
     
  2. Allow Medicare to negotiate drug prices
    Right now Medicare Part D is administered through thousands (!) of different plans each of which negotiates with the pharmaceutical industry.  That kind of fragmentation leads to higher prices for Medicare, the largest purchaser of drugs in the country.   Medicare pays more than the Veterans Administration or Medicaid for drugs.  It's hard to imagine disassembling the current Medicare Part D system in the next few years - although it would be easy to imagine some central negotiation for high cost medications that could be excluded from the Medicare Part D plans.
     
  3. Stop drug company direct to consumer advertising
    This would make TV viewing much more pleasurable - but the Supreme Court has decided that commercial speech is protected by the First Amendment, so this would require a constitutional amendment.
     
  4. Direct the FDA to consider cost effectiveness when it approves new medications
    This would require a new statute and new enabling regulations. Countries like the UK which have this in place have found that it does lower access to some new innovative drugs, and this is unpopular.  Perhaps this isn't unpopular at the level of fictional "death panels," but it would be hard to see such legislation gaining broad traction in the next few years.
     
  1. Mandate generic substitution
    Fourteen states mandate that a generic be dispensed where available unless the physician explicitly orders a brand name, and this dramatically increases generic substitution rate.  49 states allow pharmacist generic substitution based on pharmacist discretion - and only Oklahoma prohibits even this.  This battle must be fought state by state, and a small amount of lobbying goes a long way in most state legislatures.
     
  1. Provider risk sharing
    Physicians write prescriptions - and they would pay much more attention to the cost of drugs if their organizations bore financial responsibility for drug costs.  Providers do take risk for drug spending in some accountable care or bundled payment arrangements.  Provider risk sharing could also lead to physicians failing to prescribe valuable but expensive drugs, or "dumping" of patients with known chronic diseases that have expensive drug treatment. 

I'm not confident we'll lower pharmaceutical prices a lot over the next few years- especially given the new genomic drugs in the offing.  And I'm worried that the cost savings from generics might diminish through consolidation in that industry. But I'm heartened by the discussion and the bipartisan concern. Elements of the approach to lowering drug cost inflation that are being discussed now could serve as the foundation to lower costs in the years to come.
  

Jumat, 28 Juli 2017

Making America Number One in Health

Today's Managing Health Care Costs Number is 3

A large number of Republican Senators expressed doubt and concern about all three of the Republican repeal plans that failed to pass the Senate over the past few days.   Lindsay Graham pointed out that "skinny repeal"" would have disrupted the individual markets in many states. Rob Portman and Shelly Moore Capito and Dean Heller worried that Medicaid cuts would have devastated their states.   Yet all of these Senators voted for various versions of the bills they had decried.  They voted for them with mere hours (or less) to review the bills, which the Congressional Budget Office estimated would lead to 33 million more uninsured (full repeal with no replacement), 22 million more uninsured (repeal and replace), and 16 million more uninsured (skinny repeal).

John McCain stepped up and joined Lisa Murkowski and Susan Collins to stop the "skinny repeal" in the wee hours this morning - although all three have faced pressure from Mitch McConnell and taunts and threats from Donald Trump. Paul Ryan even offered promises of a Conference Committee - trying to reassure Senators that the House would not simply pass the Senate bill as is. 

I expect Zombie Obamacare Repeal will be back, and there's no guarantee that the Republicans won't get the votes in the future.    But for now, we've dodged another bullet - and efforts to throw 1/6 of the US economy into turmoil have at least been put off.

We can't fool ourselves into thinking that we have preserved a wonderful system, though. The Commonwealth Fund continues to remind us that our system is the most expensive in the world, and we have the worst outcomes of all developed countries.

Eric Schneider and colleagues of the Commonwealth Fund had a perspective piece published on nejm.org two weeks ago that pointed to four ways the US health care could transition to being the "number one" health care system in the world. It's good to read commentaries from forward looking optimists at a time when public policy seems so grim. Their suggestions didn't involve more money, but would require fundamental rethinking of how we finance, organize, and deliver health care.   Repeal of Obamacare would make it virtually impossible to achieve these goals. 

  1. Lack of access: This is driven largely by cost barriers - and has to be solved by a combination of providing more generous insurance to lower out of pocket payments - but we also will need to genuinely lower the cost of health care.   Higher deductibles and more cost sharing will just make this worse.
  2. Underinvestment in primary care:  I would have instead characterized the problem as overinvestment in expensive specialty care.  The authors would have us increase primary care capacity - although I doubt costs would come down without decreasing specialty capacity.
  3. Administrative inefficiency:  The authors note that our finance system leads to multiple layers of value-destroying costs.  These are pretty entrenched, but simplifying systems and getting rid of administrative costs would help.
  4. Disparities:  As long as disparities continue to be so striking, we will continue to have terrible outcomes for those with less access (to health care and perhaps more importantly to environments that promote healthier behavior).

It's hard to see us making progress on these four fronts when we have a Congress and Administration focused on lowering taxes on the super-rich, willing to toss tens of millions off insurance, ignoring climate change and dismantling the bipartisan legacy of environmental protection.   Red states like Texas in the vanguard of the Trumpist approach to health care and to government now see shocking increases in rates of maternal mortality, and decreases in life expectancy. 

But staving off repeal (for now) at least means we'll not be even further behind when we have the next opportunity to improve health after the departure of the current administration.   We owe a debt of gratitude to McCain (and Murkowski and Collins) for keeping us from further backsliding early this morning.  

Senin, 12 Juni 2017

Vast harms to health from the Trump agenda


Today's Managing Health Care Costs Number is 145 




The New England Journal published "Health Effects of Dramatic Societal Events — Ramifications of the Recent Presidential Election" last week.  The editorial worries that the election will cause

  • Increased racial hostility
  • Hostility in the larger environment
  • Hostility toward immigrants
  • Worries about reductions in health and social services
     
The editorialists offer providers hints about how to address their patients' emotional distress, help protect their patients' rights, and create safe spaces.  This is all well and good -but I feel that the writers are missing a broad swath of the harms that are likely to come from this presidency. I blogged about this on November 9,and the first 145 days of the Trump administration don't leave me feeling any more optimistic.

Here's the reprint of my conclusions about the profound dangers the Trump presidency poses to health of Americans:

On the macro side, many of the most important determinants of health have nothing to do with how health care is financed.
1.     Environmental protection has added years (and quality) to our lives – and Donald Trump wants to dump clean air and water regulations and burn more coal.
2.     Global warming is an existential crisis – and Donald Trump is a climate denier –and is surrounded by those who just can’t abide by science.
3.     Poverty is a major cause of bad health outcomes –and Hillary Clinton had a plan to eliminate childhood poverty.  Goodbye to that!
4.     Trade helps prevent war and increases standards of living.   Donald Trump doesn’t listen to economists.
5.     Immigration  is critical to moving the economy ahead in western democracies with low birth rates. But who cares?
6.     Diversity  leads to more intellectual achievement – hard to know this when you live in an insulated bubble with reverential syncophants.

In health care, the worries include:
1.      The exchanges are likely to be unsuccessful even if the Affordable Care Act (ACA)is not immediately repealed. They need to have more (healthy) people join. The least irresponsible Republicans have suggested that those already insured in the exchange could stay but there would be no new enrollees. That means each capped plan will get no new healthy members, and will create a death spiral.  Insurance companies know this- so there will be no exchange plans offered!
2.      Most of the innovation in payment reform has come from the Centers for Medicare and Medicaid Innovation (CMMI).   It’s part of the ACA.   If Medicare isn’t paying via alternative methods – I think fee for service will continue to dominate payment.  I’d worry we’ll see a real slowdown in provider efforts to move from “volume to value.”
3.      Insurance market reforms in the ACA have been critical to help be sure that patients are protected as consumers. This could be endangered. Remember – an employer was successful in restricting HIV care to $5000 per lifetime back in the pre-ACA days.  McGann vs. H&B Music, 1988.  An unregulated insurance market will not meet our clinical needs.  I fear that the emboldened Republican majorities could seek to preempt enlightened state regulations in health insurance.
4.      National Institute of Health funds are likely to be cut to help fund massive tax cuts for corporations and the wealthy
5.      There will be no further Medicaid expansion in the states that haven’t yet expanded it –and there will be a push to convert Medicaid into state block grants – which are likely to lead to far fewer dollars to address the health care needs for the working poor.

Since November, we've learned more about what Trump really intends to do - and if anything things look worse.   The administration all told wants a 50% cut in Medicaid, and has shown nothing but hostility toward any type of regulations, whether to protect the environment or to protect the health of workers.

Providers do need to create safe spaces, for sure. But the dangers that this Administration and its Congressional allies pose to health transcend the increasing sense of hostility.

Kamis, 18 Mei 2017

FDA regs save Medicare $80 billion

.
Today's Managing Health Care Costs Number is $80 billion



The US government dodged an $80 billion dollar bullet by requiring extensive testing before approval of Solanezumab, a new Alzheimer's Disease medication, according to new research in the New England Journal of Medicine. Eli Lilly did two human studies that found the drug no better than placebo, but subgroup analysis suggested that it might be helpful in those with especially early disease.   A trial to examine this, however, also showed no effect of the drug.


That's bad news for Eli Lilly's shareholders -but it's good news for patients who won't be given  (1) false hope (2) inevitable side effects and complications and (3) giant bills.  And it's especially good news for Medicare.  The researchers estimate that the cost of this drug to Medicare alone, were it approved, would have likely been about $80 billion over a four year period.  This good regulatory outcome was only possible because the FDA takes its job seriously and looks to approve only drugs with a credible chance of improving patient health.


The FDA mission would change, though, if it followed the recommendations of a group of scientists and advocates writing for US Against Alzheimers.  This organization (at least partially funded by the pharmaceutical industry) advocates that "the FDA should clarify for the field that a clinically meaningful benefit on a single primary endpoint of cognition or function is a sufficient basis for a New Drug Application filing." In other words, no need for new drugs to improve both cognition and function - improving one alone is enough.   There is already substantial controversy about the current group of Alzheimers drugs approved under the current approach.  These drugs consistently show modest improvement on psychometric testing which some critics feel is not clinically significant.


The current administration is clearly aiming to dramatically decrease regulation.  But easing the rigor of drug approval, in a time when new drugs are always priced at very high prices, has the potential to dramatically increase the cost of health care.   This is especially problematic in the US with direct to consumer advertising, where research shows that marketing



It's most important in the US that the FDA hold firm and not approve drugs that are of no marginal benefit, as once approved marketing (as opposed to research) can drive drugs to be blockbusters.

Senin, 20 Maret 2017

Death Panel of 535 -how many the AHCA will kill


Today’s Managing Health Care Costs Number is 24,000

Via Flickr creative commons license 

As the scheduled House of Representatives vote on the American Health Care Act is only 3 days away, and as Paul Ryan continues to tweak the legislation to satisfy conservatives (who want deeper cuts in Medicaid) and moderates (who want to make the bill less dreadful for those over 50), it’s worth looking back at research that shows how much insurance matters.

The AHCA if passed is expected to lead to an excess of between 24,000 and 48,000 deaths per year.

Julia Belluz did a  review of the work of Ben Sommers and others about a week ago on Vox.com – reprising work she did a month earlier. Giving people insurance decreases mortality.   

A New England Journal 2012 study said that 20 lives were saved annually per 100,000 who were newly enrolled in Medicaid. A 2014 study in Annals of Internal Medicine showed that health care reform in Massachusetts decreased mortality by 2.9% in the state compared to a control state that did not do health care reform in 2006 –a decrease in mortality of 8 per 100,000 insured.  

New research published in the Annals of Internal Medicineshows that cystic fibrosis patients live 10 years longer in Canada than in the United States.   Those with insurance in the US have life expectancy similar to CF sufferers north of our border.  Mortality is dramatically higher in those who are uninsured.

Median age of survival in patients with cystic fibrosis increased in both countries between 1990 and 2013; however, in 1995 and 2005, survival in Canada increased at a faster rate than in the United States (P < 0.001). On the basis of contemporary data from 2009 to 2013, the median age of survival in Canada was 10 years greater than in the United States (50.9 vs. 40.6 years, respectively). The adjusted risk for death was 34% lower in Canada than the United States (hazard ratio, 0.66 [95% CI, 0.54 to 0.81]). A greater proportion of patients in Canada received transplants (10.3% vs. 6.5%, respectively [standardized difference, 13.7]). Differences in survival between U.S. and Canadian patients varied according to U.S. patients' insurance status.

It seems like a pretty terrible time to kick 24 million people off insurance!  Of course, you don't need to read medical journals to know that!

Throughout the 2009 debate on the Affordable Care Act, there were false claims that the ACA included "death panels."  The real death panel, it turns out, is the members of the US House and Senate.  Let's hope they make the right decision.